LNP Collaborations & Partners

Our Partners

 

Genevant Sciences, Inc.

Arbutus has granted broad rights to Genevant (a company jointly owned by Arbutus and Roivant Sciences) to use Arbutus’ LNP technology.  Genevant aims to advance multiple product candidates into the clinic across RNAi, mRNA, and gene editing modalities using the Arbutus LNP and ligand conjugate delivery platforms. 

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY)

Arbutus granted a license to Alnylam to use Arbutus' LNP technology to enable RNAi therapeutic products.  Alnylam’s new drug application (NDA) for ONPATTRO™ (patisiran), an RNAi therapeutic, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of hereditary ATTR amyloidosis with polyneuropathy polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Arbutus receives royalty payments on commercial sales of ONPATTRO.  

Spectrum Pharmaceuticals, Inc.

In 2006, Arbutus licensed three liposomal chemotherapy products to Talon Therapeutics: Marqibo® (a liposomal formulation of the chemotherapy drug vincristine); Alocrest (a liposomal formulation of the chemotherapy drug vinorelbine); and, Brakiva (a liposomal formulation of the chemotherapy drug topotecan). In 2013, Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) acquired Talon Therapeutics. Spectrum has launched Marqibo® through its existing hematology sales force. Arbutus receives royalty payments based on Marqibo®’s commercial sales.

Gritstone Oncology

Gritstone Oncology was granted worldwide access to Arbutus’ portfolio of proprietary and clinically validated lipid nanoparticle (LNP) products and associated intellectual property to deliver Gritstone’s RNA-based neoantigen immunotherapy products. Gritstone will pay Arbutus an upfront payment, payments for achievement of development, regulatory, and commercial milestones, royalties, and will reimburse Arbutus for conducting technology development and providing manufacturing and regulatory support for Gritstone’s product candidates.

 

 

 

 

 

 

 Read more about our Partnered Products here.